Tirzepatide works by targeting two key hormones, GLP-1 and GIP, which regulate glucose levels and energy balance
11), which is consistent with the recent report about the Glu binding to the GLR3.3 LBD 29
Tirzepatide also demonstrated favorable effects on lipid profiles, blood pressure, and biomarkers of insulin sensitivity and liver function.The most common adverse events reported with tirzepatide and semaglutide were gastrointestinal in nature, including nausea, diarrhea, and vomiting, which were mostly mild to moderate in severity
It is critical to understand what BPC-157 is NOT: It is not an FDA-approved drug
Sometimes this change is interpreted as prominent Kupffer cells or Kupffer cell hypertrophy on H&E sections and warrants further characterization for confirmation of the endothelial cell origin